The Science and Policy Advisory Council provides a disruptive force in our dynamic healthcare forum through expert observations and recommendations on DIA's content strategies, essential research questions, key opinion leaders, collaboration partners, and trends affecting the future life sciences landscape.

Nancy Dreyer

Fellow of DIA

IQVIA

  
Nancy Dreyer, MPH, PhD, is Chief Scientific Officer and Senior Vice President at IQVIA, focusing on generating real world evidence for regulators, clinicians, patients and payers through pragmatic trials and non-interventional approaches. She is a Fellow of DIA and the International Society of Pharmacoepidemiology, a member of the PCORI Clinical Trials Methods Advisory Panel, and a Standing Consultant to the National Football League Health & Safety Executive Committee. She holds an appointment as Adjunct Professor of Epidemiology at the Gillings School of Global Public Health at the University of North Carolina and has twice been named to PharmaVOICE magazine's annual list of 100 most influential and inspiring individuals in life sciences.

Yeul Hong Kim

Korea University

  
Yeul Hong Kim, MD, PhD, is a Professor in the Department of Internal Medicine at the Korea University College of Medicine in Seoul. He is actively involved in cancer genomic research, using circulating tumor DNA, for lung and gastrointestinal cancers. His primary area of interest is in the development of new therapies in gastric cancer, colon cancer, and other gastrointestinal cancers including pancreatic cancer and biliary cancer. Dr. Kim has also served as President of the Asian Clinical Oncology Society since 2016. He is also Director of the K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, a cancer precision medicine project funded by the Korea Ministry of Health and Welfare.

Sandra A. Milligan

Fellow of DIA

Merck Research Laboratories

  
Sandra A. Milligan, MD, JD, is head of Global Regulatory Affairs & Clinical Safety (GRACS) at Merck. GRACS facilitates innovative product development, regulatory approval, and commercialization, assures safe product use, and maintains registrations for more than 200 products across international markets. In 2018, she was appointed to the DIA Science Advisory Council and serves on the International Advisory Committee for the DIA China Annual Meeting. Dr. Milligan served on DIA’s Board of Directors from 2011 to 2017, was DIA President from 2015 to 2016, and was recognized as a DIA Fellow in 2017 for her contributions to the DIA mission. She is a graduate of George Washington University School of Medicine and Georgetown University Law Center.

Samuel R. Nussbaum

EBG Advisors, Inc.

  
Samuel R. Nussbaum, MD, serves as an advisor to healthcare companies, healthcare systems, and healthcare provider organizations, as a Strategic Consultant with EBG Advisors, Inc. He is a Senior Fellow at the Schaeffer Center for Health Policy and Economics at the University of Southern California, and previously served as Executive Vice President, Clinical Health Policy, and Chief Medical Officer, for Anthem, and as Executive Vice President for BJC HealthCare. Dr. Nussbaum earned his Medical Degree from the Icahn School of Medicine at Mount Sinai.

Michael Rosenblatt

Flagship Pioneering

  
Michael Rosenblatt, MD, Chief Medical Officer of Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several biotech companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Children’s Hospitals. He earned his MD from Harvard Medical School.

Joe V. Selby

Patient-Centered Outcomes Research Institute

  
Joe Selby, MD, is the first Executive Director of the Patient-Centered Outcome Research Institute (PCORI). He previously served for nearly three decades, including 13 years as Director of Research, at Kaiser Permanente. Dr. Selby has received academic appointments at UC Berkeley, UCSF and Stanford University, and has received honors from Kaiser Permanente, the US Public Health Service, and the American Epidemiological Society. Dr. Selby served as a member of the Agency for Healthcare Research and Quality study section for Health Care Quality and Effectiveness (1999 – 2003) and was elected to membership in the US Institute of Medicine in 2009. Dr. Selby earned his MD from Northwestern University and MPH from UC Berkeley.

Jonathan Gary Sheldon

QIAGEN

  
Jonathan Sheldon, PhD, is Senior Vice President and member of the Executive Committee at QIAGEN, leading the Bioinformatics Business Unit and contributing to the QIAGEN governing body responsible for defining corporate strategy. Dr. Sheldon previously served as Global Vice President Healthcare at Oracle, and has held various CXO positions in software companies serving both the life science and healthcare sectors. Prior to the software industry, Dr. Sheldon was Head of Bioinformatics for five years at Roche (UK) Pharmaceuticals. Dr. Sheldon has been served on various advisory groups and boards including as a Director of the tranSMART Foundation, and earned his PhD in Molecular Cell Biology from the University of Cambridge.

Katrine Bosley

Advisor

Editas Medicine Inc.

  
Ms. Katrine S. Bosley has been the Chief Executive Officer and President of Editas Medicine Inc. since June 24, 2014. Ms. Bosley served as the Chief Executive Officer at Celgene Avilomics Research, Inc. She served as Vice President of Business Development at Adnexus Therapeutics Inc. She served as Vice President of Strategic Operations at Adnexus Therapeutics Inc. since August 2004. She has been a leader in emerging companies with broad platforms for innovative medicines. She has over 20 years experience in the biotechnology industry in the U.S. and in Europe.

Margaret A. Hamburg

Advisor

The National Academies of Science, Engineering and Medicine

  
Dr. Hamburg is an internationally recognized leader in public health and medicine. She is the former Commissioner of the U.S. Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service. As FDA Commissioner she was known for advancing regulatory science, streamlining and modernizing FDA’s regulatory pathways, and globalization of the agency. Before joining FDA, Dr. Hamburg was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical and biological threats. Dr. Hamburg earned her B.A. from Harvard College, her M.D. from Harvard Medical School and completed her medical residency at Weill Cornell Medical Center.